oral

The ramp-up to cold and flu season is a bad time for consumers to learn that some of their most trusted go-to products don’t actually work. An advisory committee to the U.S. Food and Drug Administration concluded unanimously in…

Engineers at the University of Cincinnati have developed a new device that can warn consumers about early risks of tooth decay from diseases such as gingivitis and periodontitis. Gingivitis, the earliest form of gum disease, is caused by…

Postpartum depression (PPD) approval based on results from two Phase 3 clinical trials; in the SKYLARK Study treatment with ZURZUVAE rapidly improved symptoms of PPD at Day 15 and as early as Day 3 with sustained effect to Day 45…

This section is Partnership Content supplied The content in this section is supplied by Business Wire for the purposes of distributing press releases on behalf of its clients. Postmedia has not reviewed the content.…

THB335 retains selectivity and potency of first-generation oral KIT inhibitor, THB001, with differentiated metabolic, distribution and physicochemical profile THB001 demonstrated evidence of pharmacodynamic (PD) activity and clinical…

New U.S. patent provides intellectual property (IP) protection until December 2040, and may qualify for term extension beyond 2040There are currently no FDA-approved treatments for PH-HFpEF, a condition affecting more than 1,600,000 North…

The majority of individuals with multiple sclerosis (MS) treat the chronic and progressive neurological disorder with oral medications, likely because of many factors, including convenience, consumer advertising and approval by health…

Although most people don't associate oral disease with serious health problems, increasing evidence shows that oral bacteria play a significant role in systemic diseases like colon cancer and heart disease. Now, new research from the…

Diabetes is a progressive disease that affects one's ability to control blood sugar levels. For many patients, the condition becomes more severe over time and blood sugar levels grow more difficult to manage. Glucagon-like peptide-1 (GLP-1)…

Presented data showing that folate receptor α (FRα)-CoStAR enhanced activity of TILs against autologous NSCLC, ovarian, and renal tumors ITIL-306, first CoStAR-TIL in clinical development, anticipated to resume clinical study in 2H 2023…